Since the approval in Canada of the first generation of polymer-EVAR graft over 9 years ago, we have been committed to serving the patients, physicians, OR staff and hospital administration who rely on us as an endovascular EVAR supplier for patients with challenging anatomies. We are fully committed to the principle of quality. We recognize that patients rely on us to provide superior products and services and we will continuously pursue excellence in all aspects of our business.

The current ALTO EVAR graft generation has demonstrated superior long-term results with lower re-intervention rates and non-existent aortic neck dilatation compromising the long term effect of EVAR therapy. This type of product performance can result in fewer added procedures, better overall outcomes and more cost-effective therapy. We also anticipate continuous product development in aortic and vascular therapies over the next 1-5 years.

Website: https://endologix.com/